Korsana (KRSA) Director Andrew Gottesdiener Receives Stock Award

What Happened

• Andrew Gottesdiener, a director of Korsana Biosciences, was granted an option (derivative award) to acquire 48,445 shares of Korsana common stock on 2026-09-09. The reported exercise price is $0.00 and the Form 4 reports $0 value for the acquisition (transaction code A — award/grant).

Key Details

• Transaction date: 2026-09-09; filing date: 2026-09-10 (filed the next day; not marked late).
• Price reported: $0.00 per share (option grant, not an open-market purchase or sale).
• Vesting: The option vests in equal monthly installments through September 9, 2029 (subject to continued service). (Footnote F1)
• Beneficial ownership note: Under an agreement, the option and underlying shares are held for the benefit of Venrock Management, LLC; Gottesdiener must exercise only at Venrock’s direction and disclaims beneficial ownership except for any pecuniary interest. (Footnote F2)
• Shares owned after transaction: Not specified in the filing.

Context

• This was a grant of an option (award), not an exercise or sale — no cash changed hands and no immediate shares were sold. Vesting schedule means the option becomes exercisable over time, subject to continued service.
• The footnote about Venrock indicates the economic interest and voting/ownership rights may be with Venrock Management, LLC rather than the director personally; this is common when insiders act on behalf of investment firms.